Baseline characteristics of metastatic CRPC patients treated with pembrolizumab
| Characteristic | n=9 patients |
| Age, median (range), years | 68 (57–88) |
| Race, n (%) | |
| African-American | 1 (11) |
| Asian | 1 (11) |
| White | 7 (78) |
| Gleason grade group, n (%) | |
| 2 | 1 (11) |
| 4 | 2 (22) |
| 5 | 6 (67) |
| Location of metastases, n (%) | |
| Bones | 5 (56) |
| Soft-tissue | 1 (11) |
| Liver | 1 (11) |
| Lymph nodes | 3 (33) |
| Initial PSA, ng/dL, median (range) | 29.3 (3.4–266) |
| Prior lines of therapy for mCRPC, n (%) | |
| 0 | 1 (11) |
| 1 | 3 (33) |
| 2 | 3 (33) |
| 3 | 1 (11) |
| 4 | 1 (11) |
| Type of prior oncological therapies, n (%) | |
| Abiraterone | 6 (67) |
| Enzalutamide | 3 (33) |
| Ketoconazole | 1 (11) |
| Apalutamide | 1 (11) |
| Docetaxel | 2 (22) |
| Cabazitaxel | 1 (11) |
| Lutetium-177-PSMA-617 | 1 (11) |
CRPC, castration-resistant prostate cancer; mCRPC, metastatic CRPC.